Multiple pre-clinical studies reviewed above suggest that the HGF/c-MET pathway is important for protecting cancer cells from insult, and so it follows that anti-HGF/c-MET therapy could be effective as an adjuvant to other cytotoxic therapies. Here, HGF is linked to cancer.